← All trials
NCT04706793
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jan 13, 2021
- Last posted
- Sep 28, 2021
- Enrollment
- 35
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Arena PharmaceuticalsLead sponsor
- Arena PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.